Scienture Secures $11M Non-Dilutive Debt, Boosting Capital Amid Q1 Revenue Surge and Margin Expansion
SCNX sits 72% above its 52-week low of $0.238 on light trading volume (0.1× avg).
Summary
Scienture Holdings reported its first-quarter 2026 financial results, highlighting a 449% year-over-year revenue increase to $56 thousand and a significant gross margin expansion to 95.6%. Crucially, the company announced securing $11.0 million in non-dilutive debt financing. This financing directly addresses the "substantial doubt about its ability to continue as a going concern" disclosed in the 10-Q filed on May 15, 2026. The $11 million non-dilutive debt is highly material for a company with a market cap of approximately $16 million, providing essential capital to support operations and growth, and mitigating immediate financial distress. Investors will monitor the deployment of this capital, the continued commercialization success of ArbliTM, and the upcoming launch of REZENOPYTM, as the company aims for anticipated profitability in 2027.
At the time of this announcement, SCNX was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.